Danilo Verge – MD, MBA
Senior Medical Advisor

Meet Dr. Danilo Verge, Senior Medical Advisor at Hemostatics

Dr. Danilo Verge is a seasoned biotech and pharmaceutical medical executive with over 25 years of extensive experience in metabolism, obesity, renal disease, and cardiovascular disease, having worked across the United States and several European countries. Most recently, Dr. Verge served as Head of Patient Safety and Medical Affairs at Zealand Pharma, based in Copenhagen, Denmark. Prior to this, he held significant leadership roles including Vice President of Global Medical Affairs for Cardiovascular, Renal, and Metabolic Diseases at AstraZeneca, working from both Gaithersburg, Maryland, and Gothenburg, Sweden, as well as Vice President of Medical Affairs at Novo Nordisk US, located in Princeton, New Jersey.

Dr. Verge also previously served in multiple international roles within Novo Nordisk, contributing significantly from its global headquarters in Copenhagen, the European regional office in Zurich, and its Spanish affiliate in Madrid. Throughout his tenure, he played a pivotal role in the development of several notable antidiabetic therapies, including insulin analogs and liraglutide.

Academically, Dr. Verge earned his Bachelor of Science degree from St. Lawrence University in Canton, New York, followed by a medical degree from the University of Buenos Aires, Argentina. He also holds an MBA from SIMI (now integrated into Copenhagen Business School) in Copenhagen.

An active member of both the American Diabetes Association and the European Association for the Study of Diabetes, Dr. Verge has contributed scholarly reviews, including one on the cardiovascular aspects of GLP-1 receptor agonists and two focused on insulin analogs. Additionally, he occasionally contributes articles to Pharmaceutical Marketing Europe, a specialized publication serving the pharmaceutical industry.